Table 2.
A summary of baseline patient characteristics in selected studies on neoadjuvant immunotherapy for resectable non-small cell lung cancer.
| Histopathology | Clinical Stage | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Neoadjuvant Immunotherapy |
Operation (%) | Male (%) | Age | Smoking History (%) |
SCC | ADC | Other | IA | IB | IIA | IIB | IIIA | IIIB | |||
| Rothschild [5] | 62 ^ | 55 | 88.7% | 35 | 52.2% | 61 | 64 | 92.3% | 22 | 37 | 8 | 0 | 0 | 0 | 0 | 67 | 0 |
| Provencio [6] * Roman [7] * |
46 | 41 | 89.1% | 34 | 73.9% | 63 | 46 | 100% | 16 | 26 | 4 | 0 | 0 | 0 | 1 | 45 | 0 |
| Cascone [8] * | 44 | 39 | 88.6% | 28 | 63.6% | 65.6 | 36 | 81.8% | 17 | 26 | 1 | 8 | 15 | 7 | 5 | 9 | 0 |
| Eicchorn [9] * | 15 | 15 | 100% | 7 | 46.7% | 59.8 | - | - | 2 | 13 | 0 | 0 | 0 | 0 | 6 | 9 | 0 |
| Tong [10] | 30 | 25 | 83.3% | 16 | 53.3% | 72 | 26 | 86.7% | 17 | 10 | 3 | 0 | 9 | 7 | 6 | 8 | 0 |
| Shu [11] | 30 | 29 | 96.7% | 15 | 50.0% | 67 | 30 | 100% | 12 | 17 | 1 | 0 | 0 | 4 | 3 | 23 | 0 |
| Bott [12] Forde [13] |
22 | 20 | 90.9% | 10 | 45.5% | 67 | 18 | 81.8% | 5 | 14 | 2 | 2 | 2 | 5 | 5 | 7 | 0 |
| Gao [14] * | 40 | 39 | 97.5% | 33 | 82.5% | 62 | 32 | 80.0% | 33 | 6 | 1 | 2 | 6 | 1 | 13 | 10 | 8 |
| Yang [15] | 24 | 13 | 54.2% | 12 | 50.0% | 65 | 23 | 95.8% | 9 | 15 | 0 | 0 | 0 | 3 | 2 | 19 | 0 |
| Wang [16] | 72 | 72 | 100% | 66 | 91.7% | 62.2 | 60 | 83.3% | 66 | 5 | 1 | 0 | 0 | 0 | 0 | 72 | 0 |
| Shen [17] | 37 | 37 | 100% | 35 | 94.6% | 62.8 | 31 | 83.8% | 37 | 0 | 0 | 0 | 0 | 0 | 3 | 28 | 6 |
| Jiang [18] * | 31 | 31 | 100% | 29 | 93.5% | 61 | 7 | 22.6% | 22 | 9 | 0 | 0 | 0 | 1 | 4 | 16 | 10 |
| Huang [19] * | 25 | 24 | 96.0% | 16 | 64.0% | 62.9 | 15 | 60.0% | 8 | 13 | 3 | 0 | 0 | 0 | 0 | 25 | 0 |
| Duan [20] | 23 | 20 | 87.0% | 22 | 95.7% | 61.8 | 22 | 95.7% | 19 | 4 | 0 | 0 | 0 | 3 | 3 | 8 | 9 |
| Chen [21] * | 12 | 12 | 100% | 9 | 75.0% | 61 | 9 | 75.0% | 4 | 6 | 2 | 0 | 0 | 0 | 0 | 7 | 5 |
| Chen [22] * | 35 | 35 | 100% | 29 | 82.9% | 62.2 | 27 | 77.1% | 26 | 7 | 2 | 0 | 0 | 0 | 0 | 31 | 4 |
| Total | 548 | 507 | 95.9% | 396 | 73.7% | IQR (61.5–65.5) |
446 | 81.7% | 56.6% | 36.9% | 4.2% | 0.1% | 0.2% | 2.3% | 6.2% | 78.0% | 1.0% |
* AJCC 8th edition TNM staging system; ^ 62/67 enrolled patients received neoadjuvant immunotherapy; SCC, squamous cell carcinoma; ADC, adenocarcinoma.